Home » Thought Leadership » Podcasts

Podcasts

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 5 posts
CBPartners' Pharma Take-Away: AMARIN's VASCEPA patent loss: is it obvious(ness)?
March 8, 2021 | Podcasts

USA Policy Expectations for a New Administration

This episode, which kicks off season two of CBPartners’ Pharma Take-away, discusses the possible evolution of healthcare and healthcare policy in the United States, and explores the changes we may expect over the next few years as a result of the presidential election party transition.

Speaking of Access: The Management of Tumor-Agnostic Therapies from CBPartners
May 20, 2020 | Podcasts

Speaking of Access: The Management of Tumor-Agnostic Therapies

Andrew Gould asks our US payer panel for their expert perspectives surrounding the management of tumor-agnostic therapies.

Speaking of Access: The Management of Tumor-Agnostic Therapies from CBPartners
May 13, 2020 | Podcasts

Speaking of Access: The Management of Gene Therapies (Now and in the Future)

Andrew Gould asks our US payer panel for their expert perspectives surrounding the management of gene therapies, both now and in the future.

CBPartners' Pharma Take-Away: AMARIN's VASCEPA patent loss: is it obvious(ness)?
May 7, 2020 | Podcasts

CBPartners’ Pharma Take-Away: AMARIN’s VASCEPA patent loss: is it obvious(ness)?

Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.

Speaking of Access: The Management of Tumor-Agnostic Therapies from CBPartners
May 5, 2020 | Podcasts

Speaking of Access: Pricing for Uncertain Indications

Andrew Gould asks our US payer panel for their expert perspectives surrounding pricing for uncertain future indications.